socalTECH

JANUARY 22, 2010

The latest numbers from the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association (NVCA), based on data from Thomson Reuters, were released this morning, finding that there was $587.8M invested in Southern California in Q4. was invested in the region. was invested in the region.

Southern California 154

Southern California Venture Capital Invest Orange County 154

socalTECH

JANUARY 22, 2010

The latest numbers from the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association (NVCA), based on data from Thomson Reuters, were released this morning, finding that there was $587.8M invested in Southern California in Q4. was invested in the region. was invested in the region.

Southern California 113

Southern California Invest Venture Capital Orange County 113

Xconomy

JULY 22, 2016

It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. And in other Amgen news, the Thousand Oaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

The Wall Street Journal reported that Cambridge, MA-based Biogen (NASDAQ: BIIB ) has drawn interest from the likes of Merck (NYSE: MRK ) and Allergan (NYSE: AGN ) as a possible takeover target. Bigelow contributed to this report. . —The fallout from the announced departure of Biogen CEO George Scangos was swift.

News 40

News Thousand Oaks Pricing Report 40

SoCal Delicious

APRIL 5, 2010

Home About Us Newsstand locations Special Section Nominations Stock Index Advertising Contact Search Subscribe Weekly Features Week in Review Top 25 Lists Top Stories Local News Opinion Calendar Ongoing Events Monthly Reports Central Coast East Ventura Nonprofits Technology Small Business Women and Co.

Santa Barbara 53

Santa Barbara Thousand Oaks Oracle Ventura 53

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Alex Lash contributed to this report. Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 40

Pricing Thousand Oaks Startup Research 40